openPR Logo
Press release

Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares should contact the Shareholders Foundation in connection with Lawsuit

09-27-2024 10:33 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in Ocugen, Inc.

The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in Ocugen, Inc.

The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in Ocugen, Inc. (NASDAQ: OCGN) shares.

Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) prior to May 2020 and continue to hold any of those NASDAQ: OCGN shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On April 1, 2024, Ocugen, Inc. filed a Form with the SEC stating that in connection with the preparation of the financial statements of the Company for the year ended December 31, 2023, it identified certain accounting errors and that as a result, it intends to restate its financial statements for the year ended December 31, 2022 and for each of the first three quarters of 2022 and 2023 in the 2023 Form 10-K, the review and preparation of which is currently ongoing..

On April 11, 2024, an investor in NASDAQ: OCGN shares filed a lawsuit against Ocugen, Inc. over alleged securities laws violations. The plaintiff alleged that the defendants made materially false and/or misleading statements and/or failed to disclose that Ocugen's financial statements from May 8, 2020 to the present were materially misstated, that Ocugen, Inc. did not have adequate internal controls, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

On August 6, 2024, the court appointed a lead plaintiff and lead counsel.

Those who purchased NASDAQ: OCGN shares should contact the Shareholders Foundation, Inc.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares should contact the Shareholders Foundation in connection with Lawsuit here

News-ID: 3671215 • Views:

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of Lyft, Inc. (NASDAQ: LYFT) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of Lyft, Inc. (NASDAQ: …
An investigation on behalf of current long-term investors in shares of Lyft, Inc. (NASDAQ: LYFT) concerning potential breaches of fiduciary duties by certain directors and officers of Lyft, Inc. (was announced. Investors who are current long term investors in Lyft, Inc. (NASDAQ: LYFT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on November 4th coming up in Lawsuit for Investors who lost money with GitLab Inc. (NASDAQ: GTLB) shares
Deadline on November 4th coming up in Lawsuit for Investors who lost money with …
A deadline is coming up on November 4, 2024 in the lawsuit filed for certain investors of GitLab Inc. (NASDAQ: GTLB) over alleged securities laws violations by GitLab Inc. Investors who purchased shares of GitLab Inc. (NASDAQ: GTLB) have certain options and there are strict and short deadlines running. Deadline: November 4, 2024. NASDAQ: GTLB stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Lawsuit filed for Investors who lost money with shares of Bumble Inc. (NASDAQ: BMBL)
Lawsuit filed for Investors who lost money with shares of Bumble Inc. (NASDAQ: B …
An investor, who purchased shares of Bumble Inc. (NASDAQ: BMBL), filed a lawsuit over alleged violations of Federal Securities Laws by Bumble Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Bumble Inc. (NASDAQ: BMBL) have certain options and for certain investors are short and strict deadlines running. Deadline: November 25, 2024. NASDAQ: BMBL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Deadline on October 28th coming up in Lawsuit for Investors in Outset Medical, Inc. (NASDAQ: OM)
Deadline on October 28th coming up in Lawsuit for Investors in Outset Medical, I …
A deadline is coming up on October 28, 2024 in the lawsuit filed for certain investors of Outset Medical, Inc. (NASDAQ: OM) over alleged securities laws violations by Outset Medical, Inc. Investors who purchased shares of Outset Medical, Inc. (NASDAQ: OM) have certain options and there are strict and short deadlines running. Deadline: October 28, 2024. Outset Medical, Inc. (NASDAQ: OM) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call

All 5 Releases


More Releases for Ocugen

Investigation announced for Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) s …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc. Investors who are current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: OCGN stocks follows a lawsuit filed against Ocugen, Inc. over alleged securities
Lawsuit filed for Investors in shares of Ocugen, Inc. (NASDAQ: OCGN)
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit over alleged violations of Federal Securities Laws by Ocugen, Inc. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: August 17, 2021. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a clinical-stage
Retinitis Pigmentosa (RP) Market 2025 : Ocugen, Inc., ReGenX Biosciences, LLC, S …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Proportions of retinal capacity, for example, the electroretinogram, demonstrate that photoreceptor capacity is decreased normally quite before symptomic night visual impairment, visual-field scotomas, or diminished visual sharpness
Retinitis Pigmentosa (RP) Market | Ocugen, Inc., ReGenX Biosciences, LLC, Sucamp …
Global Retinitis Pigmentosa (RP) Market: Overview Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced night vision and loss of peripheral vision. It gradually causes blindness. There is no definitive cure for retinitis pigmentosa. Therefore, the market for treating this genetic disorder is vastly untapped. The available therapies apply various approaches such as stem cell therapy and
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Sample Copy of
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Brochure of the